CRISPR-engineered zebrafish expression system for human type III collagen: Therapeutic efficacy in wound healing.

Summary

Using CRISPR/Cas9, the authors created a transgenic zebrafish platform producing human type III collagen with intact fibrillar structure and high thermostability. The resulting collagen composite enhanced fibroblast proliferation, reduced inflammatory cytokines, and achieved >95% wound closure in mice within 15 days, highlighting translational potential for wound dressings and anti-aging skin therapies.

Key Findings

• CRISPR/Cas9 integration of human Col3a1 into zebrafish chromosome 4 yielded a collagen composite (Col III-TC) with 45.76% extraction yield.
• The material showed intact fibrous architecture and a thermal shrinkage temperature of 71.3 °C, outperforming conventional systems.
• In vitro, Col III-TC reduced LPS-induced Tnfα, Il1b, and Il6 and increased Il10, while promoting fibroblast proliferation.
• In a murine acute wound model, Col III-TC dressings achieved >95% closure within 15 days with improved neoskin thickness and collagen deposition.

Clinical Implications

If safety and immunogenicity profiles are favorable, this collagen source could underpin next-generation wound dressings and dermal fillers or scaffolds for skin rejuvenation. Standardization and GMP-scale production will be critical for clinical translation.

Limitations

• Preclinical study without human clinical data; sample size details not specified
• Composite of human and fish collagens may pose immunogenicity/regulatory challenges

Future Directions

Undertake comprehensive toxicology and immunogenicity studies, GMP-scale production, and head-to-head comparisons with bovine/porcine collagens, followed by early-phase clinical trials in wound care and dermal regeneration.